uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Current Status of Radiopharmaceuticals for the Theranostics of Neuroendocrine Neoplasms.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Pharmacy, Department of Medicinal Chemistry.
2017 (English)In: Pharmaceuticals (Basel, Switzerland), Vol. 10, no 1, E30Article in journal (Refereed) Published
Abstract [en]

Nuclear medicine plays a pivotal role in the management of patients affected by neuroendocrine neoplasms (NENs). Radiolabeled somatostatin receptor analogs are by far the most advanced radiopharmaceuticals for diagnosis and therapy (radiotheranostics) of NENs. Their clinical success emerged receptor-targeted radiolabeled peptides as an important class of radiopharmaceuticals and it paved the way for the investigation of other radioligand-receptor systems. Besides the somatostatin receptors (sstr), other receptors have also been linked to NENs and quite a number of potential radiolabeled peptides have been derived from them. The Glucagon-Like Peptide-1 Receptor (GLP-1R) is highly expressed in benign insulinomas, the Cholecystokinin 2 (CCK2)/Gastrin receptor is expressed in different NENs, in particular medullary thyroid cancer, and the Glucose-dependent Insulinotropic Polypeptide (GIP) receptor was found to be expressed in gastrointestinal and bronchial NENs, where interestingly, it is present in most of the sstr-negative and GLP-1R-negative NENs. Also in the field of sstr targeting new discoveries brought into light an alternative approach with the use of radiolabeled somatostatin receptor antagonists, instead of the clinically used agonists. The purpose of this review is to present the current status and the most innovative strategies for the diagnosis and treatment (theranostics) of neuroendocrine neoplasms using a cadre of radiolabeled regulatory peptides targeting their receptors.

Place, publisher, year, edition, pages
2017. Vol. 10, no 1, E30
Keyword [en]
CCK2, GIP, GLP-1R, exendin-4, gastrin, neuroendocrine neoplasms, radiolabeled peptides, somatostatin receptor antagonists, theranostics
National Category
Natural Sciences
Identifiers
URN: urn:nbn:se:uu:diva-318840DOI: 10.3390/ph10010030PubMedID: 28295000OAI: oai:DiVA.org:uu-318840DiVA: diva2:1085898
Available from: 2017-03-30 Created: 2017-03-30 Last updated: 2017-03-30

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed
By organisation
Department of Medicinal Chemistry
Natural Sciences

Search outside of DiVA

GoogleGoogle Scholar

Altmetric score

Total: 143 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf